Treatment Episode Data Set (TEDS) 2022: Admissions to and Discharges from Substance Use Treatment Services Reported by Single State Agencies (Free pdf download. SAMHSA, December 11, 2024)
(Cureus, December 10, 2024)
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic A Randomized Clinical Trial (Free pdf download, JAMA Network Open, December 10, 2024)
The Many Faces of Psilocybin-Related Psychosis: A Case Series (Psychiatry Research Case Reports, December 10, 2024
The rise of novel, semi-synthetic 7-hydroxymitragnine products (Addiction, December 8, 2024)
Development and Evaluation of the Global Appraisal of Individual Needs Quick Version 4 (GAIN-Q4) for ASAM Dimension Ratings and Placement Recommendations for Adolescents and Adults (Journal of Addiction Medicine, December 7, 2024
Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine (Clinical Chemistry, December 5, 2024)
Federal Guidelines for Opioid Treatment Programs (Free pdf download. SAMHSA, December 4, 2024)
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia (Science Advances, December 4, 2024)
Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review (e-ClinicalMedicine, December 3, 2024)
A systematic review: Investigating biomarkers of anhedonia and amotivation in depression and cannabis use (JAACP Open, November 30, 2024)
Issue Brief: Co-Occurring Mental Health and Substance Use (Free pdf download, SAMHSA, November 27, 2024)
Women, gender and drugs: between research and action (Journal of Harm Reduction, November 26, 2024)
Four-year evaluation of drug-impaired driving drug concentrations (Analytical Toxicology, November 26, 2024)
Syringe services for people who inject drugs are enormously effective, but remain underused (NIDA Director's Blog, November 26, 2024)
Smoking or Vaping Cannabis and Cardiovascular Function: Is Δ‐9‐Tetrahydrocannabinol the Main Culprit (Journal of the American Heart Association, November 26, 2024)
A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome (Pharmaceuticals, November 20, 2024)
Feasibility and acceptability of a web-intervention to prevent alcohol and cannabis-impaired driving among adolescents in driver education (Addiction Science and Clinical Practice, November 20, 2024)
Feasibility and acceptability of a web-intervention to prevent alcohol and cannabis-impaired driving among adolescents in driver education (Addiction Science and Clinical Practice, November 20, 2024)
Eliminating Tobacco-Related Disease and Death, Addressing Health Disparities (U.S. Surgeon General, November 19, 2024)
Ischemic Evaluation in New‐Onset Methamphetamine‐Associated Heart Failure (Journal of the American Heart Association, November 16, 2024)
Cannabis, cannabinoids and health: A review of the evidence on risks and medical benefits (European Journal of Psychiatry and Neuroscience, November 15, 2024)
Network Watch Monitoring Drug Street Names Added to DAWN, January 2023 to August 2024 (SAMHSA, November 14, 2024)
The Circumstances Surrounding Fatal Pediatric Opioid Poisonings, 2004–2020 (Pediatrics, November 12, 2024)
Reductions in Substance Use as Outcome Targets for Treatment Development (American Journal of Psychiatry, November 8, 2024)
The Global State of Harm Reduction 2024 (Harm Reduction Journal, November 8, 2024)
Trends in Marijuana Use among Adolescents in the United States (Pediatric Reports, November 1, 2024)
Clinical Evaluation of the Cannabis-Using Patient: A Moving Target (Permanente Journal, November 5, 2024)
A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome (Pharmaceuticals, November 2, 2024)
Expanding access to addictions care: Implementation of a 24-hour healthcare provider support line (Addiction Science and Clinical Practice, November 1 ,2024)
Loneliness and cannabis use among older adults: findings from a Canada national survey during the COVID-19 pandemic (BMC Health, October 29, 2024)
A Social-Ecological Model for Understanding Cannabis Risks and Promoting Harm
Reduction (American Journal of Public Health, October 26, 2024)
Time for a public health response to gambling (Lancet Public Health, October 25, 2024)edicine Research, October 24, 2024)
Medical Cannabis: From Research Breakthroughs to Shifting Public Perceptions and Ensuring Safe Use (Integrative Medicine Research, October 24, 2024)
The Global State of Harm Reduction 2024 (Harm Reduction Journal, November 8, 2024)
Ketamine Detection and Involvement in Drug Overdose Deaths — United States, July 2019–June 2023 (CDC, November 8 2024)
Trends in Marijuana Use among Adolescents in the United States (Pediatric Reports, November 1, 2024)
Clinical Evaluation of the Cannabis-Using Patient: A Moving Target (Permanente Journal, November 5, 2024)
A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome (Pharmaceuticals, November 2, 2024)
Expanding access to addictions care: Implementation of a 24-hour healthcare provider support line (Addiction Science and Clinical Practice, November 1 ,2024)
ASAM Guest Editorial: Addressing the Addiction Treatment Gap (ASAM, October 29, 2024)
Loneliness and cannabis use among older adults: findings from a Canada national survey during the COVID-19 pandemic (BMC Health, October 29, 2024)
A Social-Ecological Model for Understanding Cannabis Risks and Promoting Harm
Reduction (American Journal of Public Health, October 26, 2024)
Listening Session: Use of High Dose Buprenorphine for the Treatment of Opioid Use Disorder (SAMHSA, October 25, 2024)
Misrepresentation of MDMA in the United States, 1999–2023 (Drug and Alcohol Dependence, October 25, 2024)
Copyright © 2024, JRW Behavioral Health Services. All Rights Reserved.
Powered by GoDaddy